Thursday May 25th 2017

Posts Tagged ‘Jugular Veins’

Amanda’s Story of CCSVI treatment and her liberation from MS

Amanda’s Story of CCSVI treatment and her liberation from MS

From YouTube: Video taken during Amanda’s visit to Bulgaria for CCSVI treatment and liberation from MS [Read More]

MS patients tell MPs about life after ‘liberation’

MS patients tell MPs about life after ‘liberation’

A group of patients with multiple sclerosis gathered on Parliament Hill Tuesday to testify how a controversial new treatment has changed their lives, as two Liberal MPs reiterated their call for more research. The patients included Steve Garvie and Lianne Webb, both of whom [Read More]

CCSVI: 20 days after procedure

CCSVI: 20 days after procedure

Hi everyone, here is my update on how I am feeling 20 days after having a venogram and ballooning of stenosed jugular veins. Posted by Mark [Read More]

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]